

Sacha I Rothschild

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7805607/publications.pdf>

Version: 2024-02-01

111
papers

3,719
citations

147801

31
h-index

155660

55
g-index

117
all docs

117
docs citations

117
times ranked

6336
citing authors

#	ARTICLE	IF	CITATIONS
1	Crizotinib Therapy for Advanced Lung Adenocarcinoma and a <i>ROS1</i> Rearrangement: Results From the EUROS1 Cohort. <i>Journal of Clinical Oncology</i> , 2015, 33, 992-999.	1.6	326
2	Targeting RET in Patients With <i>RET</i> -Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry. <i>Journal of Clinical Oncology</i> , 2017, 35, 1403-1410.	1.6	277
3	SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2872-2880.	1.6	183
4	Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study. , 2016, 4, 13.		162
5	Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1451-1457.	1.1	141
6	Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. <i>Cancer Immunology Research</i> , 2016, 4, 744-754.	3.4	131
7	Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. , 2018, 6, 40.		110
8	microRNA therapies in cancer. <i>Molecular and Cellular Therapies</i> , 2014, 2, 7.	0.2	99
9	Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2019, 8, 15352-15353.	4.6	97
10	Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 44418-44433.	1.8	95
11	Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer. <i>Journal of Pathology</i> , 2020, 250, 19-29.	4.5	92
12	A Novel Fusion Toxin Derived from an EpCAM-Specific Designed Ankyrin Repeat Protein Has Potent Antitumor Activity. <i>Clinical Cancer Research</i> , 2011, 17, 100-110.	7.0	87
13	Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK. <i>Cancers</i> , 2015, 7, 930-949.	3.7	83
14	Magnesium sensing via LFA-1 regulates CD8+ T cell effector function. <i>Cell</i> , 2022, 185, 585-602.e29.	28.9	83
15	Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic <i>ROS1</i> -Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1266-1276.	1.1	78
16	Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. <i>Cancers</i> , 2021, 13, 804.	3.7	76
17	Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1784-1791.	1.1	75
18	Src Inhibitors in Lung Cancer: Current Status and Future Directions. <i>Clinical Lung Cancer</i> , 2010, 11, 238-242.	2.6	70

#	ARTICLE	IF	CITATIONS
19	Measurement of epithelial thickness within the oral cavity using optical coherence tomography. <i>Head and Neck</i> , 2012, 34, 1777-1781.	2.0	69
20	Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. <i>Journal of Thoracic Oncology</i> , 2016, 11, 122-127.	1.1	65
21	MicroRNA-381 Represses ID1 and is Deregulated in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1069-1077.	1.1	58
22	Clinical Outcome of ALK -Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). <i>Journal of Thoracic Oncology</i> , 2017, 12, 681-688.	1.1	58
23	Gefitinib in Combination With Irradiation With or Without Cisplatin in Patients With Inoperable Stage III Non-Small Cell Lung Cancer: A Phase I Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 126-132.	0.8	46
24	PET/CT Staging Followed by Intensity-Modulated Radiotherapy (IMRT) Improves Treatment Outcome of Locally Advanced Pharyngeal Carcinoma: a matched-pair comparison. <i>Radiation Oncology</i> , 2007, 2, 22.	2.7	45
25	Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. <i>Onc Immunology</i> , 2016, 5, e1100789.	4.6	45
26	Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 121-131.	2.3	45
27	B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies. <i>Onc Immunology</i> , 2019, 8, e1512458.	4.6	42
28	MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors. <i>Lung Cancer</i> , 2017, 107, 73-83.	2.0	41
29	Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). <i>Lung Cancer</i> , 2014, 85, 306-313.	2.0	40
30	Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program. <i>Journal of Cancer</i> , 2018, 9, 250-255.	2.5	39
31	Crizotinib in the Treatment of Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 473-480.	2.6	36
32	Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. <i>Lung Cancer</i> , 2019, 130, 149-155.	2.0	36
33	Oncologist recommendation matters! Predictors of psycho-oncological service uptake in oncology outpatients. <i>Psycho-Oncology</i> , 2019, 28, 351-357.	2.3	36
34	Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1-11.	4.2	34
35	3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis. <i>Radiation Oncology</i> , 2019, 14, 32.	2.7	30
36	A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3026-3034.	7.0	29

#	ARTICLE	IF	CITATIONS
37	Tumour neoantigen mimicry by microbial species in cancer immunotherapy. <i>British Journal of Cancer</i> , 2021, 125, 313-323.	6.4	29
38	The stem cell gene <i>inhibitor of differentiation 1</i> (ID1) is frequently expressed in non-small cell lung cancer. <i>Lung Cancer</i> , 2011, 71, 306-311.	2.0	28
39	Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer. <i>OncoImmunology</i> , 2021, 10, 1988403.	4.6	28
40	Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. , 2016, 4, 47.		27
41	SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9016-9016.	1.6	27
42	Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience. <i>Journal of Cancer</i> , 2015, 6, 1148-1154.	2.5	26
43	Perioperative chemoimmunotherapy with durvalumab (Durva) in combination with cisplatin/gemcitabine (Cis/Gem) for operable muscle-invasive urothelial carcinoma (MIUC): Preplanned interim analysis of a single-arm phase II trial (SAKK 06/17).. <i>Journal of Clinical Oncology</i> , 2020, 38, 499-499.	1.6	25
44	Epigenetic Therapy in Lung Cancer – Role of microRNAs. <i>Frontiers in Oncology</i> , 2013, 3, 158.	2.8	24
45	Understanding why cancer patients accept or turn down psycho-oncological support: a prospective observational study including patients' and clinicians' perspectives on communication about distress. <i>BMC Cancer</i> , 2017, 17, 385.	2.6	24
46	Cholesteatoma triggering squamous cell carcinoma: case report and literature review of a rare tumor. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2009, 30, 256-260.	1.3	23
47	Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort. <i>Journal of Cancer</i> , 2016, 7, 2110-2116.	2.5	23
48	Immunotherapy in head and neck cancer – scientific rationale, current treatment options and future directions. <i>Swiss Medical Weekly</i> , 2018, 148, w14625.	1.6	23
49	Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors. <i>Neoplasia</i> , 2017, 19, 196-206.	5.3	22
50	Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). <i>Journal of Thoracic Oncology</i> , 2019, 14, 115-123.	1.1	21
51	Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1299.	2.8	20
52	SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics. <i>BMC Medical Informatics and Decision Making</i> , 2018, 18, 89.	3.0	18
53	Cancer immunology – development of novel anti-cancer therapies. <i>Swiss Medical Weekly</i> , 2015, 145, w14066.	1.6	18
54	Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine. <i>PLoS ONE</i> , 2016, 11, e0160807.	2.5	15

#	ARTICLE	IF	CITATIONS
55	SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1255-1262.	4.2	15
56	Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Nonâ€“Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. <i>Clinical Lung Cancer</i> , 2015, 16, 358-365.	2.6	14
57	New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 735.	2.0	13
58	Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Nonâ€“Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. <i>Clinical Lung Cancer</i> , 2017, 18, 303-309.	2.6	13
59	Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients â€“ evaluation of outcome and prognostic factors: A retrospective multicenter study. <i>PLoS ONE</i> , 2021, 16, e0253601.	2.5	13
60	Treatment, Outcome and Prognostic Factors in Renal Cell Carcinoma - A Single Center Study (2000-2010). <i>Journal of Cancer</i> , 2016, 7, 921-927.	2.5	11
61	Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. <i>Lung Cancer</i> , 2021, 156, 91-99.	2.0	11
62	EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e72966.	2.5	11
63	Lonely Driver ROS1. <i>Journal of Thoracic Oncology</i> , 2017, 12, 776-777.	1.1	10
64	Perioperative chemoimmunotherapy with durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): Primary analysis of the single arm phase II trial SAKK 06/17.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4515-4515.	1.6	9
65	Lung Cancer in Pregnancyâ€“A Forgotten Disease Entity. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1376-1378.	1.1	7
66	Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 881-889.	2.3	7
67	Malignant melanoma metastasis in the gallbladder. A case report of an unusual metastatic site. <i>International Journal of Surgery Case Reports</i> , 2020, 75, 372-375.	0.6	7
68	Extended resection for potentially operable patients with stage III nonâ€“small cell lung cancer after induction treatment. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 1587-1602.e5.	0.8	7
69	Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology. <i>Future Oncology</i> , 2014, 10, 211-217.	2.4	6
70	Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1605-1613.	4.2	6
71	Immune response and adverse events to influenza vaccine in cancer patients undergoing PD-1 blockade.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14523-e14523.	1.6	6
72	Ceritinib-a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2014, 3, 379-81.	2.8	6

#	ARTICLE	IF	CITATIONS
73	Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses. <i>European Urology Open Science</i> , 2022, 40, 16-18.	0.4	6
74	Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer. <i>Current Opinion in Oncology</i> , 2011, 23, 150-157.	2.4	5
75	Incarcerated Umbilical Hernia of Unexpected Origin: A Primitive Neuroectodermal Tumor With Early Recurrence. <i>Journal of Clinical Oncology</i> , 2014, 32, e3-e6.	1.6	5
76	Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e315-e323.	1.9	5
77	Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data. <i>Clinical Investigation</i> , 2012, 2, 387-396.	0.0	5
78	Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e151-e159.	1.9	4
79	KRAS and Immune Checkpoint Inhibitorsâ€”Serendipity Raising Expectations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 951-954.	1.1	4
80	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Studyâ€”Part 1 (Head and Neck Surgery). <i>Frontiers in Oncology</i> , 2019, 9, 1125.	2.8	4
81	Efficacy of crizotinib in ROS1-rearranged lung cancer: The European experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11035-11035.	1.6	4
82	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Studyâ€”Part 2 (Radiation Oncology). <i>Frontiers in Oncology</i> , 2019, 9, 1126.	2.8	3
83	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Studyâ€”Part 4 (Biomarkers). <i>Frontiers in Oncology</i> , 2019, 9, 1128.	2.8	3
84	Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21119-e21119.	1.6	3
85	SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)â€”A multicenter single-arm phase II trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS8584-TPS8584.	1.6	3
86	Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence. <i>Lung Cancer: Targets and Therapy</i> , 2014, 5, 51.	2.7	2
87	Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trialâ€”Updated report on progression-free and overall survival.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9066-9066.	1.6	2
88	Validation of Pretreatment Prognostic Factors and Prognostic Staging Systems for Small Cell Lung Cancer in a Real-World Data Set. <i>Cancers</i> , 2022, 14, 2625.	3.7	2
89	Crizotinib in <i>ROS1</i>-rearranged lung cancer (EUCROSS): Updated overall survival.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9078-9078.	1.6	2
90	Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e711-e718.	1.9	1

#	ARTICLE	IF	CITATIONS
91	Current and future developments of immunotherapy in lung cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 122-131.	0.5	1
92	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Studyâ€”Part 3 (Medical Oncology). Frontiers in Oncology, 2019, 9, 1127.	2.8	1
93	Tumor mutational burden assessed by a targeted NGS assay to predict clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, e14266-e14266.	1.6	1
94	SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)â€”A multicenter single-arm phase II trial.. Journal of Clinical Oncology, 2016, 34, TPS8573-TPS8573.	1.6	1
95	Radiation Therapy for HIV-Associated Diffuse Large Cell Non-Hodgkin Lymphoma. Journal of the International Association of Providers of AIDS Care, 2009, 8, 239-248.	1.2	0
96	Non-small cell lung cancer â€” ASCO 2009. Memo - Magazine of European Medical Oncology, 2009, 2, 202-205.	0.5	0
97	Update on lung cancer from the annual meeting of the American Society of Clinical Oncology 2012. Memo - Magazine of European Medical Oncology, 2012, 5, 253-258.	0.5	0
98	Transient elevation of serum carcinoembryonic antigen level in a patient with hypothyroidism. Memo - Magazine of European Medical Oncology, 2012, 5, 269-272.	0.5	0
99	Follow-up in non-small-cell lung cancer. Memo - Magazine of European Medical Oncology, 2014, 7, 97-101.	0.5	0
100	P2.03a-004 Second-line Therapy Improves Overall Survival in Primary Refractory Non Small-Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology, 2017, 12, S889.	1.1	0
101	PUB041 HGF, VEGFA and ANGPT2 Predict Clinical Benefit from Bevacizumab and Chemotherapy in Patients with Advanced NSCLC (SAKK19/09). Journal of Thoracic Oncology, 2017, 12, S1471.	1.1	0
102	SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small Cell Lung Cancer â€” A Multicentre Single-Arm Phase II Trial. SSRN Electronic Journal, 0, , .	0.4	0
103	Abstract 3987: Src regulates inhibitor of differentiation 1 (Id1) via c-Myc induced repression of microRNA-29b: Implications for invasion of lung cancer cells and their resistance against Src inhibitors. , 2011, , .		0
104	Abstract B30: Src tyrosine kinase inhibitors activate protective, ULK1-dependent autophagy by downregulating oncomir-106-393-cluster expression in non-small cell lung cancer cells. Clinical Cancer Research, 2012, 18, B30-B30.	7.0	0
105	Abstract 2263: Autophagy protects against Src tyrosine kinase inhibitor treatment in non-small cell lung cancer cells via a novel miR-106a/ULK1 pathway. , 2012, , .		0
106	Abstract 4681: The use of patient derived malignant effusions asin vitromodels for a personalized healthcare-approach in anticancer therapy. , 2014, , .		0
107	Clinical data and role of ceritinib a second-generation ALK tyrosine kinase inhibitor for the treatment of ALK positive non-small cell lung cancer. Translational Cancer Research, 2016, 5, S1173-S1176.	1.0	0
108	Tumor mutational burden assessed by a targeted NGS assay to predict benefit from immune checkpoint inhibitors in non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, e15075-e15075.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Multimodal treatment in operable stage III non-small cell lung cancer using the new TNM staging classification version 8: Long term results of a pooled analysis of three SAKK trials.. Journal of Clinical Oncology, 2018, 36, 8531-8531.	1.6	0
110	Second-line therapy to improve overall survival in primary refractory non small-cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2018, 36, e21069-e21069.	1.6	0
111	Investigation of metformin (MET) in patients with castration resistant prostate cancer (CRPC) in combination with enzalutamide (ENZ) vs. ENZ alone: A randomized, open label, phase 2 trial. SAKK 08/14â€”IMPROVE.. Journal of Clinical Oncology, 2018, 36, TPS5086-TPS5086.	1.6	0